首页 › 基金 › Enavate Sciences GP, LLC › ZBIO
Enavate Sciences GP, LLC 对 ZBIO 的持仓历史
ZENAS BIOPHARMA INC COM · 医疗保健
Enavate Sciences GP, LLC 在 Q2 2026 的 13F 申报中披露持有 ZBIO(ZENAS BIOPHARMA INC COM)3,919,159 股,市值约 US$99.5M,约占其申报组合的 28.80%,在其申报持仓中市值排名第 2 位。 Enavate Sciences GP, LLC 最近 7 个申报季度中有 7 个季度披露了 ZBIO 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Enavate Sciences GP, LLC 对 ZBIO 的持仓演变
Enavate Sciences GP, LLC 于 Q4 2024 首次披露 ZBIO 持仓:3,761,359 股(约 US$30.8M)。 该持仓在 Q4 2025 达到峰值 3,919,159 股,市值约 US$142.3M。 在 7 次申报中,Enavate Sciences GP, LLC 1 次增持、0 次减持、5 次保持不变。 最近一期申报(Q2 2026)显示持股 3,919,159 股、市值约 US$99.5M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 3.76M | $30.81M | 新进 |
| Q1 2025 | 3.76M | $29.71M | 持有 |
| Q2 2025 | 3.76M | $36.45M | 持有 |
| Q3 2025 | 3.76M | $83.50M | 持有 |
| Q4 2025 | 3.92M | $142.30M | 增持 |
| Q1 2026 | 3.92M | $76.62M | 持有 |
| Q2 2026 | 3.92M | $99.47M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ZBIO 与 13F 数据
ZBIO(ZENAS BIOPHARMA INC COM)属于医疗保健行业。我们追踪的基金中还有 68 只申报持有 ZBIO,申报仓位最大的包括:SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$80.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ZBIO 的基金
- SR ONE CAPITAL MANAGEMENT, LP 5.04M 股 · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M 股 · $102.11M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M 股 · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M 股 · $60.61M · Q2 2026
- Fairmount Funds Management LLC 2.36M 股 · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M 股 · $46.66M · Q2 2026
- Context Capital Management, LLC 35.80M 股 · $42.60M · Q2 2026
- EcoR1 Capital, LLC 789.50K 股 · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K 股 · $14.55M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 509.79K 股 · $12.94M · Q2 2026
- Rock Springs Capital Management LP 502.08K 股 · $12.74M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 490.77K 股 · $12.46M · Q2 2026
更多关于 Enavate Sciences GP, LLC
常见问题
How long has Enavate Sciences GP, LLC held ZBIO?
Enavate Sciences GP, LLC has disclosed ZBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Enavate Sciences GP, LLC's current position in ZBIO?
As of Q2 2026, Enavate Sciences GP, LLC holds 3.92M shares of ZBIO (ZENAS BIOPHARMA INC COM), valued at $99.47M, representing 28.80% of its reported portfolio and ranking #2.
Has Enavate Sciences GP, LLC been buying or selling ZBIO?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in ZBIO. The position peaked in Q4 2025 at 3.92M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.